Home / Why AGADA? / Where we help
Where we help
We apply focused expertise across critical stages of rare disease development to ensure your program meets strict regulatory expectations and advances with confidence.
Integrating specialized support into your ecosystem
AGADA Biosciences acts as a collaborative partner to deliver fit-for-purpose bioassays, rigorous efficacy studies and precision tissue handling. We step in where specialist input is most needed to protect data integrity across your global clinical sites, without demanding total control of your program.
Clinical specimen management
Protecting longitudinal data integrity with strict procedural control for frozen muscle biopsies.
Bioanalytical method validation
Pre-validated methods and fit-for-purpose bioassays designed to accurately measure critical biomarkers and accelerate rare disease drug development.
Preclinical services
Rigorous efficacy studies and established in vivo models designed to de-risk your rare disease program before human trials.
Translational strategy consulting
Successful rare disease programs begin with the right strategy. AGADA’s senior scientific team provides expert translational and regulatory guidance to help you define study objectives, select meaningful biomarker endpoints, and generate evidence that supports confident decision-making. By aligning your program with FDA and EMA expectations from the outset, we help reduce risk and accelerate development.
Discuss your program needs
Engage our senior scientists to determine how our specialized rare disease expertise can accelerate your path to the clinic.
Resolving critical execution risks
Small patient cohorts leave no margin for error. We address the technical and operational hurdles that threaten signal-to-noise ratios, keeping your rare disease data interpretable and defensible.
Central laboratory limitations with frozen tissue:
Standard central laboratories excel at processing blood and urine, but consistently struggle with frozen muscle biopsies. We resolve this by providing real-time video oversight and bidirectional shipping to ensure your samples remain viable.
Heavy bioassay validation burdens:
Developing custom methods for regulatory endpoints typically costs hundreds of thousands of dollars and takes months to complete. We provide pre-validated bioassays to bypass this validation phase and shift your program directly to deployment.
Uncertain regulatory expectations:
Agencies increasingly scrutinize early validation and data uniformity. Our senior leaders provide direct advisory input to establish the exact context of use early, ensuring your clinical endpoints meet stringent FDA and EMA expectations.
Fragmented handoffs and delays:
Transitions between isolated vendors cause costly delays and data inconsistencies. We harmonize our early discovery standard operating procedures directly with clinical protocols to drastically reduce downstream technology transfer time.
Specialized applications for rare disease programs
We leverage vast historical data and deep capability across specialized indications to ensure your efficacy studies and clinical endpoints are accurately powered and strictly fit for purpose.
Duchenne and Becker muscular dystrophies:
We provide pre-validated methods, including highly sensitive Western blots capable of detecting dystrophin biomarker levels as low as 0.25%, to capture subtle therapeutic signals.
Gene therapy efficacy:
We evaluate transgene expression and vector purity utilizing advanced bioanalytic methods like digital droplet PCR and quantitative PCR.
Complex rare disease models:
We conduct comprehensive functional evaluations, including grip strength, echocardiography and respiratory function, to accurately map disease mechanisms and therapeutic impact.
